Vanda Pharmaceuticals Inc. (VNDA) Upgraded at TheStreet

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was upgraded by analysts at TheStreet from a “d+” rating to a “c-” rating in a research report issued on Friday, May 12th.

Several other equities analysts also recently weighed in on the company. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, January 18th. CIBC restated an “outperform” rating and issued a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. Jefferies Group LLC set a $21.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, February 2nd. Finally, Oppenheimer Holdings, Inc. assumed coverage on Vanda Pharmaceuticals in a research report on Wednesday, April 12th. They set an “outperform” rating and a $21.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $20.78.

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) remained flat at $13.75 during mid-day trading on Friday. The company had a trading volume of 519,587 shares. The company’s market capitalization is $612.59 million. Vanda Pharmaceuticals has a 52-week low of $10.42 and a 52-week high of $18.00. The stock’s 50 day moving average price is $14.17 and its 200 day moving average price is $14.50.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.04. The firm had revenue of $37.42 million during the quarter, compared to analysts’ expectations of $38.35 million. Vanda Pharmaceuticals had a negative net margin of 8.85% and a negative return on equity of 10.42%. On average, equities analysts expect that Vanda Pharmaceuticals will post ($0.70) earnings per share for the current year.

WARNING: This piece was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/06/17/vanda-pharmaceuticals-inc-vnda-lifted-to-c-at-thestreet-updated-updated-updated.html.

Institutional investors have recently made changes to their positions in the company. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Vanda Pharmaceuticals by 1.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 20,191 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 191 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Vanda Pharmaceuticals by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 45,562 shares of the biopharmaceutical company’s stock valued at $638,000 after buying an additional 541 shares during the period. Rice Hall James & Associates LLC boosted its stake in Vanda Pharmaceuticals by 2.7% in the first quarter. Rice Hall James & Associates LLC now owns 27,624 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 739 shares during the period. American International Group Inc. boosted its stake in Vanda Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after buying an additional 1,491 shares during the period. Finally, Tudor Investment Corp Et Al boosted its stake in Vanda Pharmaceuticals by 3.3% in the fourth quarter. Tudor Investment Corp Et Al now owns 50,547 shares of the biopharmaceutical company’s stock valued at $806,000 after buying an additional 1,594 shares during the period. Hedge funds and other institutional investors own 93.57% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

What are top analysts saying about Vanda Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vanda Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit